IGM BIOSCIENCES, INC. (IGMS) News

IGM BIOSCIENCES, INC. (IGMS): $9.16

0.80 (+9.57%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add IGMS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#309 of 360

in industry

Filter IGMS News Items

IGMS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IGMS News Highlights

  • IGMS's 30 day story count now stands at 2.
  • Over the past 3 days, the trend for IGMS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about IGMS are DEC and VIEW.

Latest IGMS News From Around the Web

Below are the latest news stories about IGM BIOSCIENCES INC that investors may wish to consider to help them evaluate IGMS as an investment opportunity.

15 Best Falling Stocks To Buy Now

In this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, then you can skip ahead to 5 Best Falling Stocks To Buy Now. With 2023 coming […]

Yahoo | December 8, 2023

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All clinical development in hematologic oncology indications halted – – Cash runway expected to extend into second quarter 2026 – – Reduction in workforce of approximately 22 percent – MOUNTAIN VIEW, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnol

Yahoo | December 5, 2023

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted. The general meeting was held at Helio GT30 on Grev Turegatan 30 in Stockholm. For more detailed information on the content of the resolution, please see the complete notice of the extraordinary general meeting that is available on the Company's website, www.medivir.com. Minutes from the extraordinary general meeting will be provided on the said

Yahoo | December 1, 2023

Medivir to present at the Erik Penser Bank Company Event

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET.

Yahoo | November 21, 2023

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | November 19, 2023

Does IGM Biosciences, Inc. (IGMS) Have the Potential to Rally 268.31% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 268.3% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | November 16, 2023

IGM Biosciences Inc (IGMS) Reports Q3 2023 Financial Results and Pipeline Progress

Continued Clinical Development and Financial Guidance for 2023

Yahoo | November 15, 2023

IGM Biosciences Announces Third Quarter 2023 Financial Results

– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023. “During the third quarter, we continued to execute across our clinical development pipeline,”

Yahoo | November 13, 2023

IGM Biosciences to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at two upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 14 at 2:25 p.m. EST in New YorkJefferies London Healthcare Conference on Thursday, November 16 at 9:00 a.m. GMT/ 4:00 a.m. EST in London A li

Yahoo | November 7, 2023

Insiders Re-Evaluate Their US$2.02m Stock Purchase As IGM Biosciences Falls To US$349m

The recent 17% drop in IGM Biosciences, Inc.'s ( NASDAQ:IGMS ) stock could come as a blow to insiders who purchased...

Yahoo | October 9, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!